Priscilla Chan

AI in Colleges and Universities

Retrieved on: 
Wednesday, February 28, 2024
Online, Robotics, Massachusetts Institute of Technology, Public policy, College, Student, Computer science, Air force, AI, Research, Education, Intelligence, OSU, Harvard University, Ohio State University, Parent, CSAIL, Nature, University, Faculty, Priscilla Chan, School, Machine learning, Public, Medicine, Science, The, Artificial intelligence, Artificial Intelligence Laboratory, CVO

GALES FERRY, Conn., Feb. 28, 2024 /PRNewswire/ -- Colleges and universities are at the forefront of Artificial Intelligence in research and education.

Key Points: 
  • GALES FERRY, Conn., Feb. 28, 2024 /PRNewswire/ -- Colleges and universities are at the forefront of Artificial Intelligence in research and education.
  • The Break Through Tech AI hub offers a free 18-month artificial intelligence program to a diverse range of students.
  • The college also runs an online 24-week artificial intelligence boot camp, which provides learners with the skills they need to work with AI.
  • The college also offers a short course for business owners to integrate AI in their organization.

State-of-the-Art Vascular Surgery Practice Expands Its Physician Partners

Retrieved on: 
Thursday, February 15, 2024
Surgery, Health, Other Health, Newton-Wellesley Hospital, Multimedia, Patient satisfaction, Physician, Public health, Hospital, Vascular surgery, Priscilla Chan, Harvard University, Vein, Nursing care plan, Safety, University, Moyamoya disease, Emory University, Ischemia, Varicose veins, Public, Patient, Medicine, Massachusetts General Hospital, Stenosis, Research, Partnership, Medical device

Both Dr. Arous and Dr. Lancaster take a comprehensive approach to vascular health, and their commitments to advancing patient outcomes have earned them reputations as thoughtful leaders in the field.

Key Points: 
  • Both Dr. Arous and Dr. Lancaster take a comprehensive approach to vascular health, and their commitments to advancing patient outcomes have earned them reputations as thoughtful leaders in the field.
  • Including Dr. Arous and Dr. Lancaster as partners underscores TVCG’s dedication to staying at the forefront of vascular surgery and medicine.
  • Chan School of Public Health, and underwent vascular and endovascular surgery training at Massachusetts General Hospital.
  • Dr. Lancaster serves as the chief of Vascular Surgery and other leadership roles at Newton-Wellesley Hospital.

Iktos announces the appointment of Avirup Bose as Chief Business Officer

Retrieved on: 
Thursday, January 18, 2024
Synthetic media, Senior, Diabetes, DSM-IV codes, Therapy, Biology, Priscilla Chan, Drug design, Artificial intelligence, Kidney, University, Business, Novartis, AI, Business development, Drug discovery, Generative, Doctor of Philosophy, Biomedical Research, Engineering, Pharmaceutical industry

Paris (France), 18 January, 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, announces the appointment of Avirup Bose as Chief Business Officer.

Key Points: 
  • Paris (France), 18 January, 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, announces the appointment of Avirup Bose as Chief Business Officer.
  • Avirup Bose holds a PhD in Chemistry from the University of Nebraska, USA, obtained in 1997.
  • Avirup Bose, Chief Business Officer of Iktos, comments: "Artificial intelligence is revolutionizing the drug discovery process and I want to be a part of it.
  • Yann Gaston-Mathé, co-founder and CEO of Iktos, comments: "We are extremely pleased to welcome Avirup to Iktos as Chief Business Officer.

Chimerix Appoints Lisa Decker to Board of Directors

Retrieved on: 
Friday, December 29, 2023
Associate, IGM, College, Therapy, University, Business development, Holy Cross, Doctor of Philosophy, FAAN, Technology management, RN, Nektar Therapeutics, Patient, Priscilla Chan, Management

DURHAM, N.C., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Lisa Decker, Chief Business Officer at IGM Biosciences, has been appointed to Chimerix's Board of Directors.

Key Points: 
  • DURHAM, N.C., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Lisa Decker, Chief Business Officer at IGM Biosciences, has been appointed to Chimerix's Board of Directors.
  • Ms. Decker replaces Catherine Gilliss PhD, RN, FAAN, who is simultaneously retiring from the Chimerix Board after nearly 10 years of service.
  • “We are delighted to welcome Lisa to the Chimerix Board of Directors.
  • “We also thank Catherine for her valuable insight and judgement to the Chimerix Board over her tenure and for the impact she has had on the company during that time.

Chan Zuckerberg Biohub New York Will Build Technologies To Monitor Health and Eradicate Disease

Retrieved on: 
Wednesday, October 18, 2023
Science, Rockefeller University, Treatment, Lymphatic system, Cell, Artificial intelligence, Disease, Economic development, Private sector, Partnership, Hospital, Priscilla Chan, Chan Zuckerberg Initiative, New York City Economic Development Corporation, Health, Chan Zuckerberg Biohub, Physician, Workforce, Immune system, Medicine, University, Biology, Machine learning, Columbia University, Blood, Ageing, NYCEDC, CZI, Parkinson's disease, Genetics, Research, City, Tissue, Learning, Network, Travel, State government, Biomedical Research, Autoimmunity, Inflammation, Yale University, IBA Lifesciences, National Cancer Institute, Alzheimer's disease, Vaccine, Pharmaceutical industry, Management, Cancer

REDWOOD CITY, Calif., Oct. 18, 2023 /PRNewswire/ -- Today, the Chan Zuckerberg Initiative (CZI) announced the launch of a new biomedical research hub in New York City that will catalyze collaboration between leading scientific and technology institutions in the area, with the goal of solving grand scientific challenges on 10- to 15-year time horizons. The Chan Zuckerberg Biohub New York (CZ Biohub NY) brings together Columbia University, The Rockefeller University, and Yale University to create new technologies to characterize and bioengineer immune cells — with the ultimate goal of creating disease-specific "cellular endoscopes" that can detect early stages of disease in cells, monitor cell changes, and resolve diseases before they become untreatable.

Key Points: 
  • The CZ Biohub NY is the fourth research institute in the Chan Zuckerberg Biohub Network , a groundbreaking collaborative model for scientific research.
  • The Network includes the first CZ Biohub, in San Francisco , a second in Chicago , and the Chan Zuckerberg Institute for Advanced Biological Imaging in Redwood City, California.
  • In addition to the funding from CZI, the State of New York and New York City are also contributing $10 million each to the CZ Biohub NY.
  • "With a world-class faculty, cutting-edge research, and a time-tested model for innovation, the Chan Zuckerberg Biohub will help us continue to build the future of medicine in New York," Governor Hochul said.

CG Oncology Announces Key Executive Appointments in Commercialization, Medical and Manufacturing Operations

Retrieved on: 
Tuesday, September 5, 2023
Oncology, Health, Genetics, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Immortalised cell line, Upjohn, GMP, Amgen, IIT, Medical Affairs Bureau, University, Bureau of Oceans and International Environmental and Scientific Affairs, Blas, University of Maryland, College Park, GU, Record, American Society of Pediatric Hematology/Oncology, Dartmouth–Hitchcock Medical Center, Bladder cancer, Multimedia, Research, Priscilla Chan, Assistant, AbCellera, National Cancer Institute, Urology, Patient, Division, Oslo-Fergene, Hematology, IND, Sanofi, Indian Institutes of Technology, Growth, Merck Serono, SVP, Chemical engineering, Caregiver, Disease, Management, Nursing, Photocure, Seagen, Pfizer

View the full release here: https://www.businesswire.com/news/home/20230905869419/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230905869419/en/
    Ambaw Bellete, President and Chief Operating Officer, CG Oncology (Photo: Business Wire)
    “CG Oncology is at an important stage in our growth, advancing our late-stage clinical pipeline to address unmet medical needs in bladder cancer.
  • Ambaw, Swapnil and Vijay bring decades of experience and proven track records in developing immunotherapy agents from research to commercialization,” said Arthur Kuan, Chief Executive Officer, CG Oncology.
  • Previously, Vijay was the VP, Clinical Development and Medical Affairs and a member of the executive leadership team at AVEO.
  • He was also SVP of Scientific Affairs at FerGene, leading Medical Affairs, Clinical Operations, Regulatory and Clinical Development.

Endogenex™ Appoints Christopher Sorli as Chief Medical Officer

Retrieved on: 
Thursday, May 18, 2023
Men's Health, Medicine, DSM-IV codes, Insulin, Obesity, University, Billings, Montana, Metabolism, Type 2 diabetes, Billings Clinic, Duodenum, Quality of life, CMO, Priscilla Chan, Graduate, Type 2, Blood, Beth Israel Hospital, Patient, Metabolic syndrome, Single-use medical devices, Sanofi, FDA, Health, T2D, Safety, Pharmaceutical industry, Nursing, Medical device, Endocrinology, Diabetes

MINNEAPOLIS, May 18, 2023 /PRNewswire/ -- Endogenex, Inc., a clinical stage medical device company, is proud to announce the addition of Christopher Sorli, M.D., Ph.D., as Chief Medical Officer (CMO). Dr. Sorli brings a wealth of experience and clinical expertise to the company's leadership team further strengthening Endogenex's commitment to innovation that drives improvement in patient outcomes. As CMO, Dr. Sorli will play a pivotal role in shaping Endogenex's strategic medical vision and draw upon an extensive clinical background to lead medical affairs activities, collaborate with regulatory agencies, and establish relationships with healthcare professionals and patients that will advance Endogenex's position in the medical device industry.

Key Points: 
  • Bringing expertise in diabetes management, medical and regulatory affairs, clinical research, and market access
    MINNEAPOLIS, May 18, 2023 /PRNewswire/ -- Endogenex, Inc., a clinical stage medical device company, is proud to announce the addition of Christopher Sorli, M.D., Ph.D., as Chief Medical Officer (CMO).
  • Dr. Sorli joins Endogenex from Acerus Pharmaceutical where he was Chief Medical Officer leading the development of products that improve patient experience, with a primary focus in the field of Men's Health.
  • Dr. Sorli was also the Vice President and Head of Diabetes for US Medical at Sanofi where he led US medical strategy and medical activities for established and developmental portfolios of diabetes products.
  • Dr. Sorli also led The Center of Excellence in Diabetes and Metabolism, a clinical research center and metabolic surgery program.

Wyss Institute’s Lab-on-a-Molecule Drug Discovery Project Receives Funding from Northpond Labs

Retrieved on: 
Tuesday, April 4, 2023
Molecule, CFA, Boston University, Associate, Protein, Hospital, Patient, Wyss Institute, Environment, Laboratory, Disease, Heart, University, Pediatrics, Therapy, Research, Innovation, Drug discovery, Massachusetts General Hospital, Spaulding Rehabilitation Hospital, Tufts University, DNA, Harvard University, MIT, Massachusetts Institute of Technology, Wyss, Berlin, Wyss Institute for Biologically Inspired Engineering, Biochemistry, Partnership, Beth Israel Deaconess Medical Center, INSERT, Woman, RNA, Priscilla Chan, Harvard Medical School, Molecular medicine, Biological engineering, Science, Pharmacology, Medtech, Pharmaceutical industry, Vaccine, Design, Brigham, Engineering

This is the third Wyss project to which Northpond Labs has provided funding and in-kind support to ensure a pathway toward rapid technology commercialization.

Key Points: 
  • This is the third Wyss project to which Northpond Labs has provided funding and in-kind support to ensure a pathway toward rapid technology commercialization.
  • In 2020, the Wyss Institute, Northpond Labs and other collaborating institutions launched the Laboratory for Bioengineering Research and Innovation at the Wyss Institute as part of a research collaboration.
  • In 2022, the Institute, in partnership with Northpond Labs, spun out EnPlusOne Biosciences, an RNA solutions company which started as a controlled enzymatic RNA synthesis project funded by Northpond Labs in 2020.
  • Because of its potential as a next-generation drug discovery technology, the Lab-on-a-Molecule project had already been selected by the Wyss Institute as one of its 2022 Validation Projects .

Chan Zuckerberg Initiative Commits $25 Million to Speed Development of COVID-19 Treatments

Retrieved on: 
Friday, March 27, 2020
Chan Zuckerberg Initiative, Facebook, CZI, Mark Zuckerberg, Businesspeople, Priscilla Chan, Philanthropy, Economy of the United States

REDWOOD CITY, Calif., March 27, 2020 /PRNewswire/ --Today, the Chan Zuckerberg Initiative (CZI) committed $25 million to the "COVID-19 Therapeutics Accelerator" a global effort to help speed the development of treatments for COVID-19.

Key Points: 
  • REDWOOD CITY, Calif., March 27, 2020 /PRNewswire/ --Today, the Chan Zuckerberg Initiative (CZI) committed $25 million to the "COVID-19 Therapeutics Accelerator" a global effort to help speed the development of treatments for COVID-19.
  • CZI is providing $20 million, with another $5 million available based on future needs.
  • "We're excited to partner with the Gates Foundation, Wellcome, and Mastercard to help the biomedical research community quickly identify, develop, and test treatments for COVID-19," said CZI co-founders and co-CEOs Dr. Priscilla Chan and Mark Zuckerberg.
  • "The Therapeutics Accelerator will enable researchers to quickly determine whether or not existing drugs have a potential benefit against COVID-19.

Chan Zuckerberg Initiative Announces New $5 Million Funding Opportunity for Expanding Effective School Practices to Support the Whole Child

Retrieved on: 
Thursday, August 1, 2019
Facebook, Mark Zuckerberg, Nerd culture, Chan Zuckerberg Initiative, CZI, Priscilla Chan, Businesspeople, Philanthropy, Economy of the United States

This program will provide one- to two-year grants that will support up to 10 teams aiming to help schools advance exemplary practices which are helping to improve student outcomes.

Key Points: 
  • This program will provide one- to two-year grants that will support up to 10 teams aiming to help schools advance exemplary practices which are helping to improve student outcomes.
  • Through this request for applications , CZI will support educators in implementing, improving and measuring practices in their schools using the science of human adolescent learning and development.
  • This grant opportunity will accept applications from 6:00am PDT on Thursday, August 1, 2019 until 11:59pm PDT, on September 13, 2019.
  • The Chan Zuckerberg Initiative, founded by Mark Zuckerberg and Priscilla Chan in December 2015, is a new kind of philanthropic organization that brings together world-class engineering, grant-making, impact investing, policy, and advocacy work.